Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up.

Sia Viborg Lindskrog Karin Birkenkamp-Demtröder Iver Nordentoft Georgios I Laliotis Philippe Lamy Emil Christensen Derrick Renner Tine G Andreasen Naja Lange Shruti Sharma Adam C ElNaggar Minetta C Liu Himanshu Sethi Alexey Aleshin Mads Agerbæk Jørgen Bjerggaard Jensen Lars Dyrskjøt

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

ctDNA is prognostic in NAC-treated and NAC-naïve patients with more than five years follow-up and outperforms pathological downstaging in predicting treatment efficacy. Patients without detectable ctDNA at diagnosis may benefit significantly less from NAC, but additional studies are needed.

Keyphrases

circulating tumor
transcription factor
cell free
circulating tumor cells
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
genome wide analysis
smoking cessation
patient reported outcomes
case control
data analysis
nucleic acid